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Table 1
M-H OR for the Presence of a BRCA Mutation in Association with a Positive Family History of Breast Cancer,
Stratified by Age or Age at Onset
HARTGE ET AL. (1999)
WARNER ET AL. (1999): AFFECTED
WOMEN
Affected Women Unaffected Women
No. of No. of No. of
Noncarriers Carriersb OR [95%CI]c Noncarriers Carriersb OR [95%CI]c Noncarriers Carriersb OR [95%CI]c
Agea
!40 years
FH#  21 6 1.0 557 9 1.0 14 7 1.0
FH#  4 3 2.6 [.5–15.0] 114 10 5.4 [2.4–12.5] 3 6 4.0 [.8–20.6]
40–49 years
FH#  71 6 1.0 874 14 1.0 80 13 1.0
FH#  27 5 2.2 [.6–7.6] 215 9 2.6 [1.2–5.9] 31 10 2.0 [.8–5.0]
50–59 years
FH#  57 2 1.0 628 8 1.0 81 4 1.0
FH#  19 4 6.0 [1.2–30.2] 169 6 2.8 [.9–7.8] 21 5 4.8 [1.3–17.8]
60 years
FH#  46 1 1.0 611 4 1.0 95 2 1.0
FH#  25 0 .6 [.0–15.5] 189 2 1.6 [.3–8.8] 39 1 1.2 [.1–13.9]
M-H 2.6 [1.2–6.0] 3.1 [1.9–5.1] 2.6 [1.4–5.0]
P P P
Homogeneity .50 .53 .63
Unity .022 !.001 .004
a FH#= family history of breast cancer in any first-degree relative. The minus sign () indicates negative; the plus sign () indicates positive.
b Of a founder AJ BRCA1 or BRCA2 mutation.
c The logit estimate of the odds ratio was used when there was a zero cell.
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The Importance of a Family History of Breast Cancer
in Predicting the Presence of a BRCA Mutation
To the Editor:
Hartge et al. (1999) describe the prevalence of the three
founder Ashkenazi Jewish (AJ) mutations in BRCA1
(MIM 113705) and BRCA2 (MIM 600185) in 5,290
AJ volunteers from the Washington, DC, area. They re-
port an overall mutation frequency of 2.3%, ranging
from 1.2%, in those with no personal or first-degree-
relative history of breast or ovarian cancer, to 50%, in
women diagnosed with breast or ovarian cancer at age
!40 years who had at least one first-degree relative with
breast cancer diagnosed at age !50 years. The authors
demonstrate, as we and others (Karp et al. 1997; Shat-
tuck-Eidens et al. 1997; Fodor et al. 1998) have done,
that, for the 297 women in their study with breast or
ovarian cancer, the probability of carrying a BRCA1 or
BRCA2 (BRCA) mutation decreases as age at diagnosis
increases. Hartge et al. (1999, p. 965) state that, given
age-at-onset information, “family history discriminated
relatively little if the participant herself developed breast
cancer, whereas, among other participants, family his-
tory best discriminated carriers from non-carriers.” The
age of the proband is clearly a powerful predictor of
carrier probability, but our experience is that family his-
tory is an important determinant of the probability of
a mutation, in both unaffected and affected women.
Therefore, we reanalyzed Hartge et al.’s data, estimating
relative risks of carrying a BRCA mutation for each age-
at-diagnosis group (stratified by decade), in association
with a first-degree-relative family history of breast cancer
at any age (“positive family history”) and in association
with a first-degree-relative family history of at least one
case of breast cancer diagnosed at age !50 years (“pos-
itive early-onset family history”). We analyzed affected
and unaffected women separately. In affected women,
the Mantel-Haenszel (M-H) odds ratio (OR), stratified
by age at onset, for the association between a positive
family history and the presence of a founder BRCA mu-
tation, compared with a negative family history, was
2.6 (95% confidence interval [CI] 1.2–6.0, ; ta-P = .022
ble 1, first “OR” column). For unaffected women, the
M-H OR for the presence of a mutation in women with
a positive family history was 3.1 (95% CI 1.9–5.1,
; table 1, second “OR” column). For affectedP ! .001
women, the M-H OR for the presence of a BRCA mu-
tation in association with a positive early-onset family
history was 4.4 (95% CI 1.7–11.4, ; table 2,P = .003
first column). This OR is greater than that observed in
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Table 2
M-H OR for the Presence of a BRCA Mutation in Association with a Positive Family History of Early-Onset Breast Cancer,
Stratified by Age or Age at Onset
HARTGE ET AL. (1999)
WARNER ET AL. (1999): AFFECTED
WOMEN
Affected Women Unaffected Women
No. of No. of No. of
Noncarriers Carriersb OR [95%CI]c Noncarriers Carriersb OR [95%CI]c Noncarriers Carriersb OR [95%CI]c
Agea
!40 years
FH#50  23 7 1.0 614 14 1.0 17 11 1.0
FH#50  2 2 3.3 [.4–26.4] 57 5 3.9 [1.4–10.3] 0 2 7.6 [.3–173]
40–49 years
FH#50  92 8 1.0 1014 17 1.0 97 17 1.0
FH#50  6 3 5.8 [1.4–23.9] 75 6 4.8 [2.0–11.4] 14 6 2.5 [.8–7.1]
50–59 years
FH#50  70 4 1.0 743 12 1.0 90 4 1.0
FH#50  6 2 5.8 [1.0–32.6] 54 2 2.3 [.5–10.1] 12 5 9.4 [2.7–33.1]
60 years
FH#50  61 1 1.0 734 5 1.0 122 2 1.0
FH#50  10 0 2.0 [.1–51.2] 66 1 2.2 [.3–18.3] 12 1 5.1 [.548.0]
M-H 4.4 [1.7–11.4] 3.6 [2.0–6.4] 4.4 [2.1–9.2]
P P P
Homogeneity .81 .83 .40
Unity .003 !.001 !.001
a FH#50 = family history of breast cancer at age !50 years in any first-degree relative. The minus sign () indicates negative; the plus sign
() indicates positive.
b Of a founder AJ BRCA1 or BRCA2 mutation.
c The logit estimate of the odds ratio was used when there was a zero cell.
unaffected women with a positive early-onset family his-
tory (M-H OR 3.6, ; table 2, second “OR” col-P ! .001
umn). Thus, a family history of breast cancer is as pre-
dictive of the presence of a BRCA mutation in affected
women as it is in unaffected women. The M-H OR for
the unaffected and affected subgroups is similar and has
overlapping CIs. The significance levels do differ, but
this reflects the much larger size of the subgroup of un-
affected women ( ; 94.4%) compared withn = 4,993
those with breast or ovarian cancer ( ; 5.6%). Inn = 297
addition, a comparison of the strata-specific ORs in un-
affected and affected women does not reveal a consistent
pattern: none of the within-strata ORs differ statisti-
cally—the smallest P value is .38 (table 1, “OR” column
1 vs. column 2; table 2, “OR” column 1 vs. column 2).
To assess whether our reinterpretation of the Wash-
ington, DC, data set is valid, we performed the same
analysis in 412 prevalent cases of breast cancer diag-
nosed in AJ women, ascertained between November 1,
1996, and May 31, 1998, in Toronto and Montreal
(Warner et al. 1999). To compare exactly with the Wash-
ington, DC, study, we included only first-degree relatives
with breast cancer in the analyses here. The definition
of early-onset breast cancer was age at diagnosis of !50
years. The results are shown in tables 1 and 2, “OR”
column 3. Notably, the M-H ORs seen in the Canadian
study are identical to that observed in affected women
in the Washington, DC, study: M-H OR 2.6 for the
presence of a BRCA mutation in association with any
first-degree-relative history of breast cancer and 4.4 for
a positive early-onset family history. Thus, the findings
from the Canadian study support our interpretation of
the data published by Hartge et al. (1999) and lead us
to question those authors’ conclusion that the knowl-
edge gained from knowing the family history of an
affected person is “relatively small.” The weight of ev-
idence from clinical experience, from previously pub-
lished work, and from their own study supports the con-
clusion that family history and age at diagnosis of breast
cancer are both important factors in indicating the likely
presence of a mutation in BRCA1 or BRCA2.
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